Carrie Lee, MD
Hematology & Oncology · Chapel Hill, NCNPI 1538281928
Payments from drug & device makers
Across 48 payments — averaging $5756.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$152K
- Roche Products Limited$68K
- EMD Serono, Inc.$37K
- Incyte Corporation$13K
- F. Hoffmann-la Roche AG$2K
- Genentech, Inc.$2K
- plus $2K from 4 others
What the payments were for
- Speaking & faculty fees$2,42597%
- Food & beverage$462%
- Education$281%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $151,519 |
| Roche Products Limited | 9 | $68,035 |
| EMD Serono, Inc. | 5 | $37,198 |
| Incyte Corporation | 23 | $12,633 |
| F. Hoffmann-la Roche AG | 1 | $2,425 |
| Genentech, Inc. | 2 | $2,250 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,916 |
| Merck | 1 | $240 |
| Stryker | 1 | $46 |
| Pfizer | 2 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TECENTRIQ$2,425
How this compares
$276,289 in reported general payments places this provider in the 80th percentile of 358 hematology & oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 44 | $709,360 |
| TabrectaCapmatinib Hydrochloride | 13 | $300,033 |
| LorbrenaLorlatinib | 11 | $148,165 |
| LumakrasSotorasib | 13 | $137,445 |
| EliquisApixaban | 56 | $39,713 |
| Olanzapine | 25 | $365 |
| Prochlorperazine Maleate | 26 | $304 |
| Dexamethasone | 21 | $270 |
| Ondansetron Hcl | 32 | $255 |
| Oxycodone Hcl | 15 | $187 |
| Prednisone | 15 | $57 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerLorbrena, Eliquis | $28 | $187,87767 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 358 hematology & oncology providers in North Carolina.
Other hematology & oncology in Chapel Hill
- Joshua ZeidnerChapel Hill$11.2M
- Jared WeissChapel Hill$7.3M
- Autumn McReeChapel Hill$5.5M
- Christopher DittusChapel Hill$4.7M
- Eben LichtmanChapel Hill$3M
- Brandi ReevesChapel Hill$2.7M
- Jonathan SerodyChapel Hill$1.6M
- William WoodChapel Hill$1.1M
- Juneko Grilley OlsonChapel Hill$1M
- Nigel KeyChapel Hill$872K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.